| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 3rd November 2020 | Andrew A. F. Hack | 5,365,659 | Conversion of derivative | $0.00 | |
| 3rd November 2020 | Andrew A. F. Hack | 250,000 | Open or private purchase | $24.00 | $6,000,000.00 |
| 26th October 2020 | Andrew A. F. Hack | 487,500 | Grant/award etc. | $10.00 | $4,875,000.00 |
| 17th July 2020 | Robert Janssen | 50,000 | Open or private sale | $11.09 | $554,500.00 |
| 27th May 2020 | Andrew A. F. Hack | 1,000,000 | Open or private purchase | $5.00 | $5,000,000.00 |
| 19th May 2020 | Robert Janssen | 15,000 | Open or private sale | $6.33 | $94,950.00 |
| 6th May 2020 | Robert Janssen | 28,000 | Open or private sale | $4.52 | $126,560.00 |
| 5th May 2020 | Robert Janssen | 9,000 | Open or private sale | $4.43 | $39,870.00 |
| 7th April 2020 | Andrew A. F. Hack | 2,800,000 | Open or private purchase | $5.59 | $15,652,000.00 |
| 7th April 2020 | Andrew A. F. Hack | 645,667 | Open or private purchase | $7.74 | $4,997,462.58 |
Dynavax Technologies
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 5/10.
Dynavax Technologies Corp. is a biopharmaceutical company. It focuses on leveraging the body's innate and adaptive immune responses through toll-like receptor stimulation. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996.
Ticker: DVAX
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1029142
Employees: 231
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
Restructuring Charges of $9 M for the period Apr 2019 to Jun 2019 in the context of all up
Restructuring Charges of $9 M for the period Apr 2019 to Jun 2019 in the context of all up
Restructuring Charges of $5 M for the period Apr 2019 to Jun 2019 in the context of Severance and other termination benefits
Restructuring Charges of $4 M for the period Apr 2019 to Jun 2019 in the context of Stock based compensation expense
Restructuring Charges of $9 M for the period Jan 2019 to Jun 2019 in the context of all up
Fundamentals
Cash at Carrying Value: $60 M (0%)
Inventory, Net: $54 M (0%)
Assets, Current: $265 M (27%)
Property, Plant and Equipment, Net: $30 M (-4%)
Other Assets, Noncurrent: $3 M (-4%)
Assets: $329 M (18%)
Accounts Payable, Current: $3 M (-70%)
Accrued Liabilities, Current: $13 M (-10%)
Liabilities, Current: $53 M (0%)
Long-term Debt, Excluding Current Maturities: $180 M (0%)
Other Liabilities, Noncurrent: $2 M (48%)
Liabilities: $271 M (0%)
Common Stock, Value, Issued: $109 Th (29%)
Common Stock, Shares, Issued: $110 Th (30%)
Additional Paid in Capital, Common Stock: $1 B (9%)
Retained Earnings (Accumulated Deficit): $1 B (5%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $2 M (-12%)
Stockholders' Equity (Parent): $58 M (0%)
Liabilities and Equity: $329 M (18%)
Revenue: $3 M (-80%)
Research and Development: $6 M (-44%)
Restructuring Charges: $9 M (0%)
Operating Income/Loss: $23 M (-45%)
News
Diving Into Dynavax Technologies
4th January 2021
PAR Technology Corporation Announces 2020 Third Quarter Results
6th November 2020
